Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours
Sponsor: Philogen S.p.A.
A PHASE1/PHASE2 clinical study on Breast Cancer and Metastatic Melanoma, this trial is completed. The trial is conducted by Philogen S.p.A. and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — May 2022 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Philogen S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .